Reminder of Class Action Lawsuit for Picard Medical Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy PMI?
Source: Globenewswire
- Stock Price Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, dropping from $13.20 to $3.99 per share, resulting in significant losses for investors and reflecting a sharp decline in market confidence in the company.
- Fraud Allegations: The lawsuit alleges that throughout the class period from September 2 to October 31, 2025, Picard failed to disclose that its stock was subject to a fraudulent social media promotion scheme, leading investors to make decisions based on misleading information and exacerbating market uncertainty.
- Insider Trading: Investigations revealed that insiders and affiliates used offshore or nominee accounts to facilitate coordinated stock dumping during the price inflation campaign, severely harming investor interests and raising questions about the company's governance structure.
- Legal Action Deadline: Investors must file a motion by April 3, 2026, to request appointment as lead plaintiff in the class action lawsuit to recover losses incurred due to false information, underscoring the importance of investor protection.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PMI
About PMI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Stock Price Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, falling from $13.20 to $3.99 per share, resulting in significant losses for investors and reflecting a sharp decline in market confidence in the company.
- Fraud Allegations: The lawsuit alleges that throughout the class period from September 2 to October 31, 2025, Picard failed to disclose that its stock was subject to a fraudulent social media promotion scheme, misleading investors about the company's prospects and exacerbating their losses.
- Insider Trading: Investigations revealed that insiders used offshore or nominee accounts to facilitate coordinated stock dumping during the price inflation campaign, failing to disclose this information to investors, which damaged the company's reputation and triggered legal action.
- Legal Action Deadline: Investors must file a motion by April 3, 2026, to request appointment as lead plaintiff in the class action lawsuit to recover losses incurred due to false information, highlighting the importance of investor protection.
See More
- Class Action Initiation: A class action lawsuit has been filed against Picard Medical for allegedly issuing false statements between September 2 and October 31, 2025, with investors having until April 3, 2026, to seek lead plaintiff status, highlighting serious concerns over the company's transparency and integrity.
- False Promotion Allegations: The complaint alleges that Picard was involved in a fraudulent stock promotion scheme utilizing social media misinformation and impersonation of financial professionals, which artificially inflated stock prices and could lead to significant financial losses for investors.
- Insider Trading Investigation: The lawsuit also claims that insiders or affiliates used offshore accounts to facilitate coordinated share dumping, exacerbating stock price volatility and indicating potential flaws in the company's governance structure.
- Law Firm Credentials: Wolf Haldenstein Adler Freeman & Herz LLP, founded in 1888, boasts over 125 years of experience in securities litigation, dedicated to pursuing justice for investors harmed by misrepresented statements, underscoring its authority in the legal field.
See More
- Richtech Robotics Class Action: Richtech Robotics Inc. faces a class action lawsuit for the period from January 27 to January 29, 2026, alleging failure to disclose a false collaboration with Microsoft, misleading investors about the company's prospects, with a lead plaintiff motion deadline of April 3, 2026.
- Picard Medical Allegations: Picard Medical, Inc. is implicated in a class action lawsuit for the period from September 2 to October 31, 2025, accused of engaging in fraudulent stock promotion schemes and insider trading, with the same lead plaintiff motion deadline of April 3, 2026, resulting in investor losses.
- Plug Power Lawsuit Context: Plug Power, Inc. is involved in a class action lawsuit for the period from January 17 to November 13, 2025, accused of overstating the availability of funds related to a DOE loan, misleading investors about future projects, with a lead plaintiff motion deadline of April 3, 2026.
- Legal Consultation Recommendation: Investors suffering losses in these companies are advised to contact The Law Offices of Frank R. Cruz to understand their legal rights, and they need not take immediate action to become members of the class action.
See More
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Picard Medical (NYSE American: PMI) securities between September 2 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket costs.
- False Statements Uncovered: The lawsuit alleges that Picard Medical's management failed to disclose significant adverse facts regarding the company's business and securities trading during the class period, including a fraudulent stock promotion scheme involving social media misinformation and insider selling activities, misleading investors.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its success and expertise in this field.
- Investor Guidance: The firm advises investors to select qualified counsel with a proven track record, avoiding inexperienced middlemen, to ensure optimal legal support and potential recovery in the class action lawsuit.
See More
- Lawsuit Reminder: Robbins LLP reminds all investors who purchased or acquired Picard Medical (NYSE:PMI) securities between September 2, 2025, and October 31, 2025, that a class action has been filed, indicating potential losses for shareholders.
- Fraud Allegations: The complaint alleges that Picard Medical failed to disclose its involvement in a fraudulent stock promotion scheme utilizing social media misinformation and impersonated financial professionals, misleading investors significantly.
- Stock Price Crash: On October 24, 2025, Picard Medical's stock price plummeted by 70%, dropping from $13.30 to $3.99 per share, and has since continued to decline to approximately $2.00 per share, reflecting a severe crisis of market trust for the company.
- Shareholder Action: Shareholders can file papers by April 3, 2026, to serve as lead plaintiffs in the class action, representing other shareholders and highlighting the urgent need for improved corporate governance to protect investor rights.
See More
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Picard Medical, Inc. (NYSE American:PMI) for securities transactions between September 2, 2025, and October 31, 2025, urging investors to contact the firm before April 3, 2026, to protect their rights.
- False Statement Allegations: The complaint alleges that Picard Medical made false and misleading statements during the class period, engaging in a manipulation scheme to fraudulently inflate its stock price, resulting in investor losses when the truth emerged, highlighting severe governance and transparency issues within the company.
- Shareholder Rights Protection: The Schall Law Firm specializes in securities class action lawsuits and encourages affected shareholders to reach out for free legal consultations, emphasizing the importance of legal assistance in safeguarding investor rights.
- Legal Proceedings Update: The class action has not yet been certified, meaning investors are not represented by an attorney during this period, and those who choose not to act will remain absent class members, reminding investors to stay informed about the legal process to protect their interests.
See More








